{
    "nct_id": "NCT03886831",
    "official_title": "A Phase 1, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients With Advanced Solid Tumors and Hematologic Malignancies",
    "inclusion_criteria": "* Metastatic or advanced solid tumor; or advanced diffuse large B-cell lymphoma; or advanced mantle cell lymphoma; or relapsed myelodysplastic syndrome, acute myeloid leukemia or chronic myelomonocytic leukemia; or relapsed myelofibrosis. All malignancies must be refractory to established therapies\n* Biomarker-selected solid tumors\n* Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1\n* Adequate organ function (bone marrow, hepatic, renal, cardiovascular)\n* Female patients of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use an effective method of contraception during the trial\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Primary malignancies of the Central Nervous System(CNS) or uncontrolled CNS metastases\n* Requirement of pharmacologic doses of glucocorticoids\n* Prior treatment with chimeric antigen receptor T cells (CAR-T cells)\n* HIV positive; known active hepatitis B or C\n* Known hypersensitivity to any of the components of PRT543\n* Prior allogeneic bone marrow transplant; autologous hematopoietic transplantation less than 100 days since transplantation",
    "miscellaneous_criteria": ""
}